Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

類似資料

• Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
  著者:: Qingsheng Xu (17078830)
  出版事項: (2025)
• Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
  著者:: Sied Kebir (15048732)
  出版事項: (2025)
• Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
  著者:: Sied Kebir (15048732)
  出版事項: (2025)
• Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
  著者:: Sied Kebir (15048732)
  出版事項: (2025)
• Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
  著者:: Sied Kebir (15048732)
  出版事項: (2025)